Halia Therapeutics
Tracked across 3 events · 19 articles · First seen May 12, 2026 · Last active Jun 29, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Halia Therapeutics announced positive final Phase 2 results for its drug ofirnoflast (HT-6184) in lower-risk myelodysplastic syndrome (LR-MDS) and appointed Win Myint as Chief Medical Officer, strengthening its clinical development capabilities.
May 12, 2026 · 6 articles
Regulatory
Impact: Halia Therapeutics received Fast Track designation for its drug ofirnoflast (HT-6184), which is a significant milestone that will expedite the development and review process, potentially leading to earlier market entry and increased revenue.
Jun 15, 2026 · 7 articles
Tech
Impact: Halia Therapeutics is a US-based biotechnology company that developed HT-4253, the investigational therapy being evaluated in the trial. The company has also established a new office in Abu Dhabi.
Jun 29, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Halia Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard